𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Telomere length of in vivo expanded CD4+CD25+regulatory T-cells is preserved in cancer patients

✍ Scribed by Dominik Wolf; Holger Rumpold; Christian Koppelstätter; Guenther A. Gastl; Michael Steurer; Gert Mayer; Eberhard Gunsilius; Herbert Tilg; Anna M. Wolf

Publisher
Springer-Verlag
Year
2005
Tongue
English
Weight
356 KB
Volume
55
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CD4+CD25+ regulatory T cells in patients
CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies : Possible involvement of regulatory T cells in disease progression
✍ Tetsuro Sasada; Motohide Kimura; Yuka Yoshida; Michiyuki Kanai; Arimichi Takabay 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB

## Abstract ## BACKGROUND Active suppression by CD4^+^CD25^+^ regulatory T cells plays an important role in the down‐regulation of the response of T cells to foreign and self antigens. Experimental tumor models in mice revealed that regulatory T cells inhibit antitumor immune responses. The purpos

IL-2 induces in vivo suppression by CD4+
IL-2 induces in vivo suppression by CD4+CD25+Foxp3+ regulatory T cells
✍ Susan Brandenburg; Takeshi Takahashi; Maurus de la Rosa; Marko Janke; Gabriele K 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 403 KB

## Abstract Interleukin‐2 (IL‐2) treatment is currently used to enhance T cell‐mediated immune responses against tumors or in viral infections. At the same time, IL‐2 is essential for the peripheral homeostasis of CD4^+^CD25^+^Foxp3^+^ regulatory T cells (Treg). In our study, we show that IL‐2 is a